🧾 What This Document Is

This is a PRE 14A preliminary proxy statement for Zevra Therapeutics. Think of it as an "invitation and information packet" for the company's 2026 Annual Meeting of Stockholders. It outlines what shareholders will vote on and provides the details they need to make informed decisions.

👉 Why it matters: As a shareholder, this document tells you what's on the ballot, who is running the company, and how it performed. Your vote directly influences the company's direction.

🏢 What The Company Does

Zevra Therapeutics is a commercial-stage biotech company focused on rare diseases. Their mission is to develop and deliver life-changing treatments for patients with serious, underserved conditions.

👉 In simple terms: They are no longer just a research company. They now have an approved drug on the market (MIPLYFFA for NPC) and are building a business around it while advancing other treatments in their pipeline. They describe themselves as building a "durable rare disease company."

💰 Financial Highlights (2025)

The proxy includes key financial results from 2025, showing the company's transition to a commercial entity.

• Total Net Revenue: $106.5 million
• MIPLYFFA Net Revenue: $87.4 million (Their lead product for Niemann-Pick disease type C (NPC) was a major contributor).
• GAAP Diluted Earnings Per Share (EPS): $1.35
• Major Asset Sale: They sold a Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million, providing a significant cash infusion.

👉 Why it matters: These numbers show the early commercial success of their first major drug, MIPLYFFA, and a large one-time cash boost from the PRV sale. This establishes their financial foundation.

🚀 Key Strategic Moves & Pipeline Progress

Beyond finances, the company highlighted several important operational and strategic actions:

• Commercial Launch: Reached over 40% of diagnosed NPC patients in the first full year of MIPLYFFA's U.S. launch, with 161 patient enrollments.
• European Expansion: Submitted a Marketing Authorization Application (MAA) for arimoclomol (the active ingredient in MIPLYFFA) in the EU in July 2025.
• Pipeline Advancement: Their Phase 3 DiSCOVER trial for celiprolol (another rare disease drug) was about one-third enrolled by year-end 2025.
• Portfolio Focus: Made the difficult decision to scale back promotion of OLPRUVA, directing resources to higher-priority programs.
• Leadership & Location: Appointed Alicia Secor to the Board and relocated headquarters to Boston to access talent and partnerships.

👥 Board of Directors & Governance

The board structure and composition are central to this proxy.

• Current Board: 8 members, but will reduce to 7 at the annual meeting. The board is highly independent (7 of 8 directors).
• Director Nominees (Proposal 1): Shareholders are asked to elect Douglas W. Calder and Corey Watton for new 3-year terms.
• Classified Board Proposal (Proposal 3): This is a major governance change. The board recommends approving an amendment to phase out its "classified" structure. Currently, directors serve staggered 3-year terms. If approved, all directors elected at or after the 2027 meeting will be elected annually.
• Other Proposals: Ratify Ernst & Young LLP as the auditor for 2026 (Proposal 2).

👉 Why it matters: The board oversees the company's strategy and executive team. Proposal 3, if passed, would make the entire board accountable to shareholders on an annual basis starting in 2027, increasing shareholder influence.

🔮 What's Next: 2026 Outlook

The CEO's letter outlines the path forward, emphasizing execution and value creation.

• Commercial Focus: Maximize the U.S. opportunity for MIPLYFFA and advance the European regulatory review.
• Pipeline Catalysts: Continue enrolling the Phase 3 celiprolol trial and explore accelerated regulatory pathways with the FDA.
• Financial Strength: Mention of a strong balance sheet following the PRV sale and strategic transactions (like repaying a term loan).
• Operational Priorities: Deliver therapies, advance the pipeline, foster a high-performing culture, and maintain a robust corporate foundation.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

• A commercial product generating significant revenue (MIPLYFFA).
• A large cash position from the PRV sale.
• A late-stage pipeline asset (celiprolol) in a large trial.
• A governance proposal (declassification) that aligns with shareholder-friendly practices.

⚠️ Risks & Challenges:

• The long-term commercial trajectory and market potential for MIPLYFFA in the ultra-rare NPC disease.
• The inherent risk and cost of advancing late-stage clinical trials (celiprolol).
• The successful execution of the EU launch for arimoclomol.
• The need to continue funding operations and pipeline development from revenues and its cash reserves.

🧠 The Analogy

Zevra is like a specialized restaurant that just opened its first popular location. After years of perfecting the recipe (drug development), they finally opened the doors (commercial launch of MIPLYFFA) and are seeing strong early customers (patient enrollments). They used a one-time windfall (PRV sale) to pay off their construction loan and build cash reserves. Now, they're focused on keeping that first location running smoothly, planning a franchise in Europe, and perfecting a new signature dish (celiprolol) for the menu.

🧩 Final Takeaway

This proxy captures Zevra at a pivotal moment: transitioning from a development-stage company to a commercial one with a successful launch. Shareholders are being asked to endorse the current board and consider a significant governance change (de-classification) that would give them more direct annual control. The company's near-term future hinges on executing its commercial strategy and advancing its pipeline with its strengthened financial position.